Management Team

Eric Schlorff
Eric Schlorff
Chief Executive Officer

Since 2019, Eric Schlorff has served as the Chief Executive Officer of SeaStar Medical, responsible for the management, strategy, and operations of the company. He has extensive experience in financial planning and managing large, complex organizations and as well as deep knowledge of SeaStar Medical’s business operations, including the scientific basis, regulatory requirements and sales and marketing channels.

Prior to joining SeaStar Medical in 2016, Mr. Schlorff spent more than 20 years at Dow Chemical Company, serving in served in multiple role, including Global Director of Alternative Investments for the Dow Chemical Pension Plan, Global Finance Leader for Crop Protection & Seeds at Dow AgroSciences, Global Market Intelligence Leader at Dow AgroSciences, Global Financial Manager of Royalties at Dow Agrosciences, Senior Investment Manager of Alternative Investments at Dow Chemical Company, New Business Development of Pharmaceuticals at Dow Chemical Company, Global Financial Analyst within the New Businesses division at Dow Chemical Company, and Global Financial Analyst within Dow AgroSciences at Dow Chemical Company.

Mr. Schlorff has a bachelor’s degree in chemistry and biology from Mac Murray College, an M.S. in pharmacology from Southern Illinois University School of Medicine and a master’s in business administration from University of Illinois Urbana-Champaign.

LinkedIn

Twitter

Col. (Ret) Kevin Chung, MD, FCCM, FACP
Col. (Ret) Kevin Chung, MD, FCCM, FACP
Chief Medical Officer

Dr. Kevin Chung, a renowned expert in burns, multi-organ support, and extracorporeal therapies, is Chief Medical Officer of SeaStar Medical where he is responsible for the strategy, direction, and execution of the company’s clinical development plans as the company develops and commercializes extracorporeal therapies.

Prior to joining SeaStar Medical, Dr. Chung served as professor and Chair of the Department of Medicine, and professor of Surgery, at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Earlier in his career, he served as Chief of the Department of Medicine at Brooke Army Medical Center in San Antonio. Dr. Chung deployed as the Chief, Intensive Care Unit, for the 86th Combat Support Hospital in Baghdad, Iraq 2008, and as Director, Joint Combat Casualty Research Team in Bagram, Afghanistan 2012.

He is a 1995 graduate of the United States Military Academy at West Point and a 1999 graduate of Georgetown University School of Medicine.

Dr. Chung has authored over 300 peer reviewed manuscripts, reviews, editorials, and book chapters, and has been an invited speaker for over 150 lectures internationally.

LinkedIn

Twitter

Michael Messinger
Michael Messinger
Chief Financial Officer

Mr. Messinger has more than two decades of experience and leadership in financing and accounting for drug discovery and development organizations. He currently serves as a member of the board of directors of Filament Health Corp. and a strategic consultant to various biotechnology companies. Mr. Messinger most recently served as Chief Financial Officer of ContraFect Corporation, where he led the company through its Nasdaq IPO in 2014, multiple financing rounds, including investments from Pfizer Inc., and a $90 million contract with BARDA (Biomedical Advanced Research and Development Authority). Prior to joining ContraFect, Mr. Messinger held senior financial roles at Lexicon Pharmaceuticals, Inc. and Coelacanth Corporation. He started his career as an auditor at Ernst & Young LLP. Mr. Messinger received his B.B.A. degree in accounting from the University of Michigan.